$CLYM News

Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target

Climb Bio Launches $100M At-The-Market Common Stock Offering Via Jefferies

Why Is Climb Bio Stock Gaining Friday?

Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price Target

BTIG Maintains Buy on Climb Bio, Raises Price Target to $20

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Announces Initial Data From Its Ongoing Phase 1b Portion Of Its Phase 1b/2a Study Evaluating Budoprutug In Adults With Primary Immune Thrombocytopenia

Guggenheim Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $35

BTIG Reiterates Buy on Climb Bio, Maintains $19 Price Target

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight Series

Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio to Present at Upcoming Investor Conferences

HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20

Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17